-
Prochlorperazine-Induced Neuroleptic Malignant Syndrome
2026-09-04
This case report highlights neuroleptic malignant syndrome (NMS) after standard-dose Prochlorperazine in an older adult, despite initially unremarkable or only borderline laboratory findings. Its principal contribution is a clinically grounded diagnostic and treatment framework emphasizing medication history, neurological examination, and early benzodiazepine- and amantadine-based management.
-
Prenatal Esketamine Exposure and Offspring Neurobehavior
2026-09-04
A rat study examined how gestational esketamine exposure affects offspring neurodevelopment from early hippocampal growth through adolescent behavior. Its integrated design linked reduced neural progenitor proliferation and impaired neuronal maturation with synaptic dysfunction, altered CREB and NMDAR-associated signaling, and deficits in cognition, memory, and emotional behavior.
-
Nanoparticle PTEN mRNA Therapy for Trastuzumab Resistance
2026-09-03
The reference study developed tumor-microenvironment-responsive nanoparticles for systemic PTEN mRNA delivery, aiming to restore tumor-suppressor activity and reverse trastuzumab resistance in HER2-positive breast cancer models. Its central contribution is the integration of pH-triggered PEG detachment, intracellular mRNA release, and PI3K/Akt signaling pathway inhibition into one delivery strategy.
-
RITA (NSC 652287) Assay Workflow Guide
2026-09-03
Learn how to use RITA as an MDM2-p53 interaction inhibitor while separating growth arrest from true cell killing. This workflow combines dose-response testing, apoptosis assays, time-resolved viability measurements, and orthogonal DNA-damage readouts for more interpretable cancer biology data.
-
HyperScribe All in One mRNA Synthesis Kit Plus 1 Guide
2026-09-02
Build ARCA-capped, 5mCTP- and ψUTP-modified, polyadenylated mRNA in one coordinated workflow for translation studies, RNA vaccine development, and immune-response assays. The kit’s integrated capping, DNase treatment, and poly(A) tailing steps help reduce handoffs between transcription and functional testing.
-
Rapamycin and Ferroptosis: A Translational mTOR Lens
2026-09-02
Rapamycin (Sirolimus) is more than a canonical mTOR pathway reagent: it can serve as a causal probe for how growth, metabolism, immune activation, and mitochondrial stress intersect. This article places Rapamycin alongside sphingolipid–HIF-1 biology to help translational researchers separate established evidence from testable hypotheses.
-
Sorafenib (BAY-43-9006) in Cancer Research
2026-09-01
Sorafenib, also known as BAY-43-9006, is an orally bioavailable multikinase inhibitor used as a cancer biology research tool. Its benchmark activities span RAF signaling, VEGFR-mediated angiogenesis, PDGFR signaling, tumor proliferation inhibition, cell assays, and xenograft studies.
-
CAY10499 for Lipid Flux and TAM Assays
2026-09-01
CAY10499, an inhibitor of human hormone sensitive lipase, offers a precise way to perturb lipid hydrolysis while studying macrophage and tumor metabolism. This article connects its biochemical profile with extracellular-vesicle-driven TAM research and provides practical assay-design guidance without overstating translational evidence.
-
TUNEL Apoptosis Detection Kit: Glioma Workflow
2026-08-31
Use a colorimetric TUNEL workflow to visualize apoptotic DNA fragmentation in glioma cells and tissue sections without relying on fluorescence microscopy. This guide translates a recent Chrysanthemum indicum L. anti-glioma study into practical controls, optimization steps, and quantitative brightfield readouts.
-
Indomethacin in Inflammation Research
2026-08-31
Indomethacin is a nonsteroidal anti-inflammatory drug with COX inhibition, PPAR activity, and reported membrane-ordering effects. These properties support controlled inflammation research and lipid metabolism study designs, but they also require solvent, pathway, and specificity controls.
-
Abiraterone Acetate in 3D Prostate Cancer Models
2026-08-30
Use Abiraterone acetate as a controlled CYP17 inhibitor challenge in patient-derived prostate spheroids, while separating target biology from limitations in compound exposure and model context. This workflow combines 3D viability, androgen receptor activity inhibition, biomarker profiling, and practical troubleshooting for more defensible prostate cancer research.
-
Cyclosporin Variants in Mitochondrial Membranes
2026-08-29
The reference study compared cyclosporins B, C, D, and E using NMR spectroscopy, molecular dynamics, and calcium-dependent liver mitochondrial swelling assays. Its central finding was that cyclosporins B–D retained cyclosporin A-like mitochondrial pore inhibition, whereas the more rigid cyclosporin E was inactive, linking peptide flexibility with membrane-associated activity.
-
O-GlcNAcylation Rewires Glycolysis in Bone Formation
2026-08-28
The reference study identifies O-GlcNAcylation as a necessary metabolic and signaling intermediate in Wnt-stimulated osteoblastogenesis. Its key mechanistic finding is that Wnt3a modifies PDK1 at Ser174, stabilizing PDK1 and redirecting glucose metabolism toward aerobic glycolysis, bone formation, and fracture healing.
-
Indomethacin: Practical Workflow and QC Guide
2026-08-28
Indomethacin is a nonsteroidal anti-inflammatory drug used as a pharmacological perturbation for cyclooxygenase, inflammation, lipid metabolism, and membrane studies. This guide explains solvent selection, controls, assay interpretation, and storage; it should not be treated as a pathway-specific probe or as a substitute for directly matched literature evidence.
-
HIV-1 Remodels Nuclear Pores to Infect Resting T Cells
2026-08-27
The reference study identifies nuclear import at the nuclear pore complex as a decisive barrier to HIV-1 infection in resting CD4+ T cells. It shows that cell–cell spread activates CD4–LCK–CDK1 signalling, remodels nucleoporins without requiring cell-cycle entry, and licenses viral capsid entry into the nucleus.